Lonza increases its offer

Basel Tower, Switzerland – Lonza Corporate ©Lonza Ltd.

The pharmaceutical industry global partner Lonza increases its offer and will invest no less than 500 million Swiss francs in Switzerland. This news is eagerly awaited, as the project will seriously strengthen the position of the CDMO. Lonza is already a significant player and partner in the pharmaceutical industry. It offers a wide range of services and products from the discovery phase and API manufacturing to the product formulation. This new investment will increase this offer. It consists in the construction of a large-scale pharmaceutical filling and finish plant and thus completes the CDMO’s offering. 

Located in Stein, not far from the facilities dedicated to the production of clinical drug products, the new site will be designed with sustainable development considerations in mind. To reduce the company’s carbon footprint, a photovoltaic roof will be installed and responsible energy use will be adopted. Completion is scheduled for 2026. To be continued…

Stay informed of the latest pharma news. Subscribe now!